Human Reproduction, Vol. 12, No. 11, pp. 2347-2357, 1997
© 1997 European Society of Human Reproduction and Embryology
Opinion |
The 1995 pill scare revisited: anatomy of a non-epidemic
McGill University, Montreal, Canada and Stanford University Palo Alto, California, USA
Correspondence: 1To whom correspondence should be addressed at: Stanford University, PO Box 5788, Stanford, CA 94309–5788, USA
Two years after the October 1995 pill scare that received worldwide attention, this synthesis of evidence goes back to the earliest research on risks of first generation oral contraceptives (OCs). It also covers epidemiological data published since, emphasising the 1995–1996 findings. Late breaking data are also examined. The key issue: are there differences in the risk profiles of second and third generation OCs. The ultimate question is: did any epidemics of venous thromboembolism (VTE) occur? This synthesis of evidence leads to the following conclusions and observations: (i) all OCs on the market are becoming progressively safer; (ii) relative risks of about 2 for VTE, even if real, are clinically unimportant and of no public health significance; (iii) the weak odds ratios contrasting third and second generation OCs, ranging from 1.5 to 2.3 in the 1995–1996 studies are more likely explained by bias than by a causal relationship; (iv) incidences of VTE among users of any OC have been declining over the past three decades; (v) absolute rates of VTE for third generation OC users reported in 1995–1996 are lower than those for users of second generation OCs in 1988 and 1991; (vi) there is no difference in risk of VTE between first starters on second generation OCs versus first starters on third generation OCs; (vii) users of third generation OCs are at much lower risk of acute myocardial infarction than users of second generation OCs; (viii) among users of any OC, the occurrence rates of stroke are low, they are declining, and no differences between second and third generation OCs are apparent; (ix) 2 years after the pill scare there are no epidemics of VTE; (x) there have been excessive rates of therapeutic abortions in some countries; and (xi) the benefit–risk ratio is favourable for users of any OC.
Key words: cardiovascular events/epidemiology/oral contraceptives/venous thromboembolism
Submitted on July 16, 1997; accepted on September 18, 1997.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Drife Putting risk into context Obstet Gynaecol (Lond), January 1, 2007; 9(1): 42 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Lewis, K. D. MacRae, D. Kuhl-Habich1, R. Bruppacher, L. A.J. Heinemann, and W. O. Spitzer The differential risk of oral contraceptives: the impact of full exposure history Hum. Reprod., June 1, 1999; 14(6): 1493 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mills and I. R. Edwards The combined oral contraceptive pill - are poor communication systems responsible for loss of confidence in this contraceptive method? Hum. Reprod., January 1, 1999; 14(1): 7 - 10. [Full Text] [PDF]
|
|